{"ok":true,"trend":{"id":618102,"platform":"news","region":"global","key":"gedatolisib toxicity and treatment education in hr+/her2− mbc","title":"Gedatolisib Toxicity and Treatment Education in HR+/HER2− mBC","url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQR3FMdDU5QXQxcDVFNllUUGlpZ2hlYTFlblJqNGpNb1JORDVJNEZDMEIxd0J4eHNLOG1GVldBd09xVmdYU3dPRllBWFlSWmRHRFBZYkwxR2hwS3JIVGZ2MXNZQTFkMVRTQlotWDlZcFNFMkQ2M3VkSDNRcE11bzJzTGNuU0F3cW9EUGFiQjliV2V5Q0JfNnJNT0lB?oc=5","first_seen":"2026-10-01T14:21:21.377324Z","last_seen":"2026-10-01T18:27:17.634183Z","last_rank":21,"peak_rank":6,"last_volume":null,"peak_volume":0,"seen_count":3,"score":0.51796875,"category_hint":"education","section":"life","category":"education","summary":"Attention is turning to gedatolisib, an investigational PI3K/mTOR inhibitor being studied for hormone receptor-positive, HER2-negative metastatic breast cancer. Coverage from CancerNetwork highlights the drug's toxicity profile and the need for better patient and clinician education around managing side effects during treatment. The discussion centres on how safety monitoring and awareness may shape its use if the therapy advances toward approval.","why":"Ongoing clinical development of gedatolisib is prompting education about its safety profile in metastatic breast cancer care.","tone":"neutral","entities":["gedatolisib","HR+/HER2− metastatic breast cancer","CancerNetwork"],"summarized_at":"2026-10-01T14:23:28.643573Z","meta":{"via":"scan","lang":"en","term":"education","source":"CancerNetwork","published":"Thu, 01 Oct 2026 14:11:28 GMT"},"nw":null,"promo":null,"kind":null,"importance":null,"hidden":false,"hide_reason":null,"judged_at":null,"title_en":"Gedatolisib Toxicity Focus in HR+/HER2− Metastatic Breast Cancer","section_name":"Life","category_name":"Education","timeline":[{"captured_at":"2026-10-01T14:21:21.377324Z","rank":6,"volume":null},{"captured_at":"2026-10-01T15:43:17.950234Z","rank":11,"volume":null},{"captured_at":"2026-10-01T18:27:17.634183Z","rank":21,"volume":null}],"posts":[{"platform":"news","url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQR3FMdDU5QXQxcDVFNllUUGlpZ2hlYTFlblJqNGpNb1JORDVJNEZDMEIxd0J4eHNLOG1GVldBd09xVmdYU3dPRllBWFlSWmRHRFBZYkwxR2hwS3JIVGZ2MXNZQTFkMVRTQlotWDlZcFNFMkQ2M3VkSDNRcE11bzJzTGNuU0F3cW9EUGFiQjliV2V5Q0JfNnJNT0lB?oc=5","author":"CancerNetwork","title":"Gedatolisib Toxicity and Treatment Education in HR+/HER2− mBC","snippet":null,"posted_at":"2026-10-01T12:12:35Z","likes":null}],"elsewhere":[],"window":"7d"}}